Integrative assessment of the effectiveness and safety of outpatient use of Picamilon
Randomized study in people · 2024
- What was studied
- 44 stage I patients: 23 oral-only and 21 sequential parenteral/oral; 60 days of treatment
- Main finding
- Cognitive scores and sleep questionnaires improved during two active Picamilon schedules. There was no untreated or placebo group.
MoCA cognitive score · 24.9 → 26.5 → 28.3 points · Pooled active-treatment sample; the abstract does not map all three quoted values to specific visits · Reported serial assessments · p=0.022 and p<0.001 as reported
Reported findings and study design
Cognitive scores and sleep questionnaires improved during two active Picamilon schedules. There was no untreated or placebo group.
Open randomized comparison of 44 stage I cerebral-ischemia patients: oral-only 23; sequential intramuscular/oral 21; 60 days of treatment and a later follow-up.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| MoCA cognitive score | 24.9 → 26.5 → 28.3 points | Pooled active-treatment sample; the abstract does not map all three quoted values to specific visits · Reported serial assessments · p=0.022 and p<0.001 as reported |
| Sleep improvement | 50% at visit 3; 84% at visit 4 | Questionnaire-defined improvement; not measured sleep stages · End of 60-day treatment; then 1.5-month follow-up |
| Fedin neurological symptom score | 11.9 ± 8.3 → 6.0 ± 6.1 → 2.77 ± 4.43 points | Baseline → visit 3 → visit 4 · p<0.0001 for both follow-up comparisons |
| Neurological improvement | 77% reported improvement | Within the treated sample |
| Autonomic-function normalization | 29% | No significant difference between active schedules · p=0.024 as reported |
| Treatment completion | 44/44 completed | 23 oral-only and 21 sequential treatment |
| Tolerability and adverse events | 98% rated good tolerability; abstract reports <8.6% adverse events | Denominator and event-versus-patient definition must be checked before converting to counts |
| Between-schedule sleep comparison | No significant final difference | Oral-only versus sequential treatment · p=0.508 |
These are changes during active treatment, not placebo-adjusted effects. The 2024 and 2025 patient series may overlap. Source percentage descriptions are retained without inventing adverse-event counts.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- Open comparison of two active schedules; no placebo or untreated group.
- Questionnaire sleep outcomes are not measured sleep stages.
- Possible overlap with the 2025 report remains unresolved; do not sum cohorts.
- Biomarker change does not demonstrate fewer cardiovascular events.
Related publications may describe some of the same participants or experiments.
Source details
Publisher HTML article
Publisher original abstract and selected HTML results checked; detailed table-by-table reconstruction remains open
Sources checked
Citation
Danilov AB, Shindryaeva NN, Borodulina IV, Lunegov TD. Integrative assessment of the effectiveness and safety of outpatient use of Picamilon Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 124(7). PMID 39113452
Study source ↗ · DOI 10.17116/jnevro2024124071119 · Bibliography entry · Link to this summary